Association Between Tamsulosin and Serious Ophthalmic Adverse Events in Older Men Following Cataract Surgery

Chaim M. Bell, MD, PhD
Wendy V. Hatch, OD, MSc
Hadas D. Fischer, MD
Geta Cernat, MD, MSc
J. Michael Paterson, MSc
Andrea Gruneir, PhD
Sudeep S. Gill, MD, MSc
Susan E. Bronskill, PhD
Geoffrey M. Anderson, MD, PhD
Paula A. Rochon, MD, MPH

Context Both benign prostatic hyperplasia (BPH) and cataract formation are common in older men. The α-adrenergic receptor blocker tamsulosin is frequently prescribed to treat BPH, and research suggests this drug may increase the intraoperative difficulty of cataract surgery. No studies have documented whether use of tamsulosin or other α-blocker drug therapies affect the risk of serious postoperative adverse events.

Objective To assess the risk of adverse events following cataract surgery in older men prescribed tamsulosin or other α-blocking drugs used to treat BPH.

Design, Setting, and Patients Nested case-control analysis of a population-based retrospective cohort study using linked health care databases from Ontario, Canada. We included all men aged 66 years or older who had cataract surgery between 2002 and 2007 (N = 96128).

Main Outcome Measures A composite of procedures signifying retinal detachment, lost lens or lens fragment, or endophthalmitis occurring within 14 days after cataract surgery. The risk of these adverse events was compared between men treated with tamsulosin or other α-blockers and men with no exposure to these medications in the year prior to cataract surgery. We separately examined the association of drug exposure that was either recent (within the 14 days before surgery) or previous (15-365 days before surgery).

Results Overall, 3550 patients (3.7%) in the cohort had recent exposure to tamsulosin and 7426 patients (7.7%) had recent exposure to other α-blockers. Two hundred eighty-four patients (0.3%) had an adverse event. We randomly matched 280 of the cases to 1102 controls according to their age, surgeon, and year of surgery. Adverse events were significantly more common among patients with recent tamsulosin exposure (7.5% vs 2.7%; adjusted odds ratio [OR], 2.33; 95% confidence interval [CI], 1.22-4.43) but were not associated with recent exposure to other α-blockers (7.5% vs 8.0%; adjusted OR, 0.91; 95% CI, 0.54-1.54) or to previous exposure to either tamsulosin (=1.8% vs 1%; adjusted OR, 0.94; 95% CI, 0.27-3.34) or other α-blockers (2.9% vs 2.1%; adjusted OR, 1.08; 95% CI, 0.47-2.48). This corresponds to an estimated number needed to harm (NNH) of 255 (95% CI, 99-1666).

Conclusions Exposure to tamsulosin within 14 days of cataract surgery was significantly associated with serious postoperative ophthalmic adverse events. There were no significant associations with exposure to other α-blocker medications used to treat BPH.


©2009 American Medical Association. All rights reserved.

See also p 2044 and Patient Page.
IFIS for patients taking tamsulosin and undergoing cataract surgery.\textsuperscript{15-17} However, the warnings and noted precautions in reference materials focused only on the added intraoperative difficulty associated with tamsulosin and did not mention postoperative adverse events.\textsuperscript{18}

Each year, approximately 5\% of elderly US residents undergo cataract procedures.\textsuperscript{19} Because 1\% to 5\% of male patients are taking tamsulosin at the time of surgery, a sizable proportion of patients may experience IFIS.\textsuperscript{12} However, few studies have been large enough to assess the connection between tamsulosin exposure and postoperative complications. In addition, it is unclear whether proximity of therapy to the surgery is important or whether complications are equally likely with \(\alpha\)-blockers other than tamsulosin.\textsuperscript{7}

Accordingly, we undertook a large, population-based analysis of postoperative adverse events experienced by patients who were prescribed tamsulosin or other \(\alpha\)-blockers at the time of cataract surgery. To assess specificity of effect, we also studied exposure to proton pump inhibitors—drugs for which an increased risk of adverse events would not be expected.

**METHODS**

**Overview**

We used several linked administrative databases and a nested case-control design to study serious ophthalmic adverse events experienced by Ontario residents who underwent cataract surgery between 2002 and 2007. Cases were those who experienced an adverse ophthalmic surgical outcome within 14 days of cataract surgery. Controls were selected from those patients who had cataract surgery but who had no such adverse event. The study protocol was approved by the Research Ethics Board at Sunnybrook Health Sciences Centre, Toronto. The analysis was performed at the Institute for Clinical Evaluative Sciences, which has statutory authority to conduct health services research without consent using anonymized administrative data.

**Data Sources**

The province of Ontario has a universal health insurance program that covers all 12 million residents. Records from 3 health administrative databases were linked using encrypted unique identifiers. The Ontario Drug Benefit database contains highly accurate records of all outpatient prescriptions dispensed to patients aged 65 years or older.\textsuperscript{20,21} The Ontario Health Insurance Plan database contains information on inpatient and outpatient physician services. This database has excellent reliability for surgical procedures.\textsuperscript{21} The Ontario Registered Persons database contains demographic and vital status information on all residents. All 3 databases are virtually complete for the variables used in this research.\textsuperscript{21}

**Cohort Identification**

We used the Ontario Health Insurance Plan database to identify patients aged 66 years or older who had cataract surgery between April 1, 2002, and June 16, 2007. For those who had multiple procedures over the accrual period, we studied the first.

Because BPH was the only indication for tamsulosin for formulary coverage in Ontario and it is the only US Food and Drug Administration-labeled indication, women were excluded. We also excluded those who had other eye procedures in combination with their cataract surgery, those who had eye procedures other than cataract surgery in the preceding 5 years, those prescribed topical cyclosporine within 90 days of surgery, those who died within 14 days of surgery, and those who had a second cataract surgery within 14 days.

**Postoperative Adverse Events: Case Ascertainment**

Case patients had a physician service claim for any 1 of 4 procedures (vitrectomy, vitreous aspiration or injection, dislocated lens extraction, or air or fluid exchange) between 1 and 14 days after cataract surgery. Procedures occurring on the same day as the surgery were not included. These procedures were a composite outcome for serious postoperative ophthalmic adverse events and served as indicators of retinal detachment, lost lens or lens fragment, and suspected endophthalmitis.\textsuperscript{22,23} Lost lens or lens fragment was defined as any patient on whom the procedure for dislocated lens extraction was performed. Retinal detachment was defined as any patient on whom an air or fluid exchange was performed. Suspected endophthalmitis was defined as any patient on whom a vitrectomy or vitreous aspiration or injection was performed, which was not in tandem with a lost lens or lens fragment or air or fluid exchange. Outcomes were recorded regardless of who patients saw for their postoperative care.

**Selecting Controls**

From the subgroup of patients who did not experience an adverse ophthalmic event, we selected up to 4 controls per case. Controls were randomly selected and matched to cases according to the patient’s year of birth (within 3 years of case’s birth), the surgeon who performed the cataract procedure, and the year the cataract surgery was performed (within 1 year of the case’s surgery). This approach minimized bias due to patient age, surgeon volume and complication rates, and changes in surgical technique over time.\textsuperscript{22}

**Assessing Exposure to \(\alpha\)-Blockers**

The drug exposure of primary interest was the relatively selective \(\alpha_{1a}\)-receptor blocker, tamsulosin. We also assessed exposure to other, less selective \(\alpha\)-blocking agents: alfuzosin, doxazosin, prazosin, and terazosin. All of these drugs were covered by the Ontario Drug Benefit Program during the period of study and were identified using specific drug identification numbers recorded on paid claims in the Ontario Drug Benefit Database. Alfuzosin, doxazosin, and terazosin all had indications for BPH. Doxazosin, prazosin, and terazosin all had indications for hypertension.

We created 3 mutually exclusive exposure groups: (1) the recent-exposure group were individuals whose most re-
recent prescription for an α-blocker included the period of the 14 days before cataract surgery, incorporating a 20% grace period to accommodate nonadherence. This period was based on previous observations27,28; (2) the previous-exposure group were those who filled a prescription in the year prior to surgery but who did not qualify for the recent-exposure group (ie, those whose drug supply [plus a 20% grace period] ended between 15 and 365 days before cataract surgery); and (3) the no-exposure group were patients who had no exposure to an α-blocking drug in the 365 days before surgery.

Because some patients received more than 1 study drug before surgery, we used a hierarchical approach to the exposures. We considered a recent exposure to a medication to be more important than a previous exposure, and exposure to tamsulosin (the drug of primary interest) to be more important than exposure to another α-blocker. For example, a patient who satisfied the criteria for recent tamsulosin exposure could have a prior or overlapping prescription for another α-blocker but would remain in the recent-tamsulosin category.

**Covariates**

Our analysis adjusted for several potential confounders (Table 1). Individual-level income status was based on the Ontario Drug Benefit program's income test for prescription copayment. A count of the number of medications dispensed in the year prior to surgery was used as a validated measure of comorbidity.25 Those prescribed an anti-diabetic medication in the year before surgery were defined as having diabetes. We also adjusted for topical eye medications prescribed within 90 days of cataract surgery. These drugs were grouped according to indication or mechanism of action to avoid overfitting the statistical model.

**Statistical Analysis**

We used descriptive statistics to characterize cases and controls. Conditional logistic regression was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) for the association between adverse events and the following: recent tamsulosin exposure, recent exposure to another α-blocker, previous tamsulosin exposure, and previous exposure to another α-blocker. All groups were compared with the referent group of no exposure. A multivariate model was fitted to adjust for potential confounding characteristics. All analyses were performed using SAS version 9.1 (SAS Institute Inc, Cary, North Carolina). For the study's case-control ratio of 4, independence in the probability of exposure among cases and controls, and a type I error probability of 0.05, our study had 88% power to reject the null hypothesis of an OR of 1 for a clinically significant unadjusted odds ratio of 2.5. This was based on a cataract surgery cohort of approximately 100 000 men, 3% taking tamsulosin at the time of surgery, and 0.3% experiencing a postoperative adverse event.12,22,26,27 We used a 2-sided test of significance at the P<.05 level.

**Test for Specificity**

We assessed specificity of effect using proton pump inhibitors as a *tracer exposure*, an exposure for which we would not expect an association with serious ophthalmic adverse events from cataract surgery. Those analyses excluded patients who had any exposure to tamsulosin or another α-blocker in the 365 days preceding cataract surgery.

**Estimate of Absolute Risk of Recent Tamsulosin Exposure**

We calculated the event rate for our composite end point over the 5-year study period for all patients undergoing cataract surgery to estimate the absolute risk associated with recent tamsulosin exposure. We applied the estimated adjusted OR for recent tamsulosin exposure from the nested case-control analysis to the baseline event rate in the cohort to estimate the number needed to harm (NNH, for which, $\text{NNH} = 100 \times \left[\frac{1}{\text{absolute risk increase}}\right]$, and absolute risk increase = estimated absolute risk [OR × baseline event rate]−baseline event rate).

**RESULTS**

We identified 96 128 older men who had cataract surgery over the 5-year study period. There were 3550 patients (3.7%) who had recent exposure to tamsulosin and 1006 (1.1%) who had previous exposure to tamsulosin. There were 7426 patients (7.7%) who had recent exposure to other α-blocking medications and 1683 (1.1%) who had previous exposure. We identified 284 case patients (0.3%) who experienced an adverse event in the 14 days after surgery. Of these 284 cases, 175 had a procedure for lost lens or lens fragment, 35 for retinal detachment, and 26 had both. One hundred had suspected endophthalmitis. Of the 284 cases, 280 were matched to 1102 control patients; more than 96% of cases
were matched to 4 controls. The average age of cases and controls was 77 years, and both groups were dispensed an average of approximately 10 medications in the year preceding cataract surgery. Over one-fifth of the sample had diabetes and low-income status, respectively (Table 1).

In our primary analysis of adverse events following cataract surgery, 21 case patients (7.5%) and 30 control patients (2.7%) received tamsulosin in the 14 days before surgery. This resulted in an adjusted OR of 2.33 (95% CI, 1.22-4.43; Table 2). For patients prescribed other α-blockers, 21 case patients (7.5%) and 88 control patients (8.0%) received the medication in the 14 days preceding surgery (adjusted OR, 0.91; 95% CI, 0.54-1.54).

Those who had previous exposure to tamsulosin were not at elevated risk for complications (≤ 5 case patients [≤1.8%] vs 11 control patients [1.0%]; adjusted OR, 0.94; 95% CI, 0.27-3.34). Previous exposure to other α-blockers also was not associated with elevated risk (8 case patients [2.9%] vs 23 control patients [2.1%]; adjusted OR, 1.08; 95% CI, 0.47-2.48). For our test of specificity, neither recent nor previous exposure to proton pump inhibitors was associated with increased risk for a postoperative adverse event (Table 2).

### Table 2. Postoperative Adverse Outcomes for Patients Receiving α-Blocker Medications

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>No. (%) of Patients</th>
<th>Odds Ratio (95% Confidence Interval)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Case (n = 280)</td>
<td>Control (n = 1102)</td>
</tr>
<tr>
<td>No use&lt;sup&gt;b&lt;/sup&gt;</td>
<td>226 (80.7)</td>
<td>950 (86.2)</td>
</tr>
<tr>
<td>Recent exposure&lt;sup&gt;c&lt;/sup&gt; Tamsulosin</td>
<td>21 (7.5)</td>
<td>30 (2.7)</td>
</tr>
<tr>
<td>Other α-blocker drugs&lt;sup&gt;c&lt;/sup&gt;</td>
<td>21 (7.5)</td>
<td>88 (8.0)</td>
</tr>
<tr>
<td>Proton pump inhibitors&lt;sup&gt;d&lt;/sup&gt;</td>
<td>26 (9.3)</td>
<td>126 (11.4)</td>
</tr>
<tr>
<td>Previous exposure&lt;sup&gt;e&lt;/sup&gt; Tamsulosin</td>
<td>≤5 (≤1.8)&lt;sup&gt;f&lt;/sup&gt;</td>
<td>11 (1.0)</td>
</tr>
<tr>
<td>Other α-blocker drugs&lt;sup&gt;e&lt;/sup&gt;</td>
<td>8 (2.9)</td>
<td>23 (2.1)</td>
</tr>
<tr>
<td>Proton pump inhibitors&lt;sup&gt;e&lt;/sup&gt;</td>
<td>11 (3.9)</td>
<td>42 (3.8)</td>
</tr>
</tbody>
</table>

<sup>a</sup> We are unable to display information on cell sizes less than 6.

<sup>b</sup> Adjusted for diabetes, low income status, number of drugs taken in the previous year, antibiotic or antiviral treatment, glaucoma treatment, anti-inflammatory treatment, combination treatment of steroids and antibiotics, mydriatics, and antiludery medication.

<sup>c</sup> The no-exposure group were patients who had no exposure to an α-blocker in the 365 days before surgery.

<sup>d</sup> The recent exposure group comprised individuals whose most recent prescription for an α-blocker ended within 14 days of cataract surgery, including a 20% grace period to accommodate nonadherence.

<sup>e</sup> Other drugs include alfuzosin, doxazosin, prazosin, or terazosin.

<sup>f</sup> Analysis for proton pump inhibitors excluded patients who had any exposure to tamsulosin or another α-blocker in the 365 days preceding cataract surgery.

Our findings are strengthened by the inclusion of consecutive surgeries, the population-based nature of the sample, and the negative finding within the tracer population of proton pump inhibitor users. Because the cataract surgery and adverse outcomes were linked regardless of what physician the patients saw postoperatively, cases were lost to follow-up only when patients sought postoperative care outside the province—an extremely infrequent occurrence. The case-control design is well-suited to this question because serious cataract surgical complications are rare, and nesting the analysis within a predefined cohort helped to identify suitable controls. Furthermore, matching according to age, surgeon, and year of surgery served to minimize bias.

Our overall adverse event rate is comparable with those from other studies. However, most studies examining the effect of tamsulosin have been small and have focused on the intermediate measure of IFIS. Furthermore, few have studied the effect of timing of tamsulosin therapy or controlled for potential confounders, such as surgeon volume and ocular and disease morbidity. Thus, our study contributes on several fronts.

Why did we find an effect with tamsulosin but not with other α-blocking drugs? This may relate to differences in receptor affinity between tamsulosin and other related medications. It is believed that tamsulosin is more highly selective for α<sub>1</sub>-adrenergic receptors than other α-blocker drugs. These particular receptors are present in bladder-neck smooth muscle and in the iris dilator muscle. Blockage of the iris dilator allows unopposed action of the parasympathetically innervated iris constrictor muscle and loss of iris tone, resulting in the clinical syndrome of IFIS. In contrast, the design of the study and the hierarchical method of ascribing medication exposure precluded us from fully evaluating the effect of other α-blocking drugs. In many cases, those prescribed tamsulosin were previously prescribed another α-blocking drug so disentan-
TAMSULOSIN AND SERIOUS OPHTHALMIC ADVERSE EVENTS

Discontinuing tamsulosin may not be a good clinical strategy because this can result in acute urinary retention, which also has significant morbidity and mortality risks. This must be weighed against our estimated NNH of 255. Third, we could not determine whether replacing tamsulosin with another -blocking medication would change the risks related to surgery because IFIS can occur many months after stopping tamsulosin therapy.

Our study has several important limitations. First, we used administrative health data, which lacks clinical information for detailed case-mix adjustment. Noting the difficulty of the cataract surgery using clinical records may explain some of the observed differences in patient outcomes. However, our analysis did account for patient age, sex, and many potential confounders that could complicate cataract surgery such as diabetes and other eye diseases.

Second, our claims data confirm only that prescriptions were filled; not whether the drugs were ingested. Third, although our study included 96 128 consecutive cataract surgeries, the small number of patients in our subgroup analyses may have limited power to detect significant effects. Fourth, many study patients were accrued after published evidence of an association between tamsulosin and IFIS. We could not determine whether surgeons anticipated IFIS or used medical or surgical interventions such as iris expansion hooks, intracameral phenylephrine, or preoperative atropine. Such interventions might reduce risks for complications. Furthermore, a knowledge of tamsulosin exposure might lead to closer postoperative scrutiny, thereby increasing the diagnosis of adverse events. However, our study period also included several years prior to the first description of IFIS in 2005, and data from this earlier era would not be subject to increased surveillance and ascertainment bias. Moreover, the adverse events we selected are usually dramatic, quickly present to medical attention, and require procedural interventions.

Fifth, we did not assess whether high doses of the individual -blocking drugs were associated with changes in risk. Again, these types of subgroup analyses would have limited power due to the low adverse event rates in cataract surgery. Sixth, we excluded adverse events occurring more than 2 weeks after surgery, which may underestimate the true adverse event rate. However, most such cases would usually present within this time frame.

Seventh, our estimate of retinal detachment may be an underestimate because we captured retinal detachments repaired via vitrectomy and air or fluid exchange but not those repaired by scleral buckling. Similarly, our estimate of lost lens or lens fragment may be an underestimate because the procedure of dislocated lens extraction may not be performed if the lost lens or lens fragment is not considered to compromise visual outcome. Eighth, our hierarchical approach to drug exposure assessment did not account for possible interaction or additive effects of -blocking medications. Ninth, since we did not measure IFIS directly, we are unable to definitively connect the adverse outcomes with IFIS. Tenth, our study was restricted to men older than 65 years. The findings may still pertain to younger individuals, although they may have a lower absolute risk of adverse events.

Finally, because our data sources do not specify which eye underwent cataract surgery, it is possible that we captured postoperative complications occurring in the contralateral (nonoperative) eye. However, requiring such care within 2 weeks of surgery should be extraordinarily rare. Similarly, the procedures counted as adverse events can sometimes be unrelated to cataract surgery (eg, macular pathology from diabetes and macular degeneration). Still, it is unlikely that procedures for these conditions would be performed in the nonoperative or fellow eye within 2 weeks of cataract surgery. On balance, we believe it unlikely that any of these limitations would invalidate our principal finding of an increased risk of adverse events in patients dispensed tamsulosin in the weeks immediately preceding surgery.

Our finding that tamsulosin exposure is associated with an increased risk of postoperative complications concurs with prior studies of intraoperative adverse events. We believe that this is the first large study with an adequate study design to describe this effect and provide a population-based risk estimate (something that can only be done using population-based observational research). It is unclear whether drug discontinuation prior to surgery reduces this risk. Because the combination of cataract surgery and tamsulosin exposure is relatively common, patients should be properly apprised of the risks of drug therapy and preoperative systems should focus on the...
identification of tamsulosin use by pa-
tients. In this way, surgeons can plan and
prepare for a potentially more com-
pliated procedure or refer to some-
one with more experience.

Author Contributions: Dr Bell had full access to all
of the data in the study and takes responsibility for
the integrity of the data and the accuracy of the
data analysis.

Study concept and design: Bell, Hatch, Fischer,
Paterson, Gill, Anderson, Rochon.

Acquisition of data: Bell, Cernat.

Analysis and interpretation of data: Bell, Hatch, Fischer,
Paterson, Cernat, Paterson, Gruenei, Gill, Bronskill, Anderson,
Rochon.

Drafting of the manuscript: Bell, Hatch, Fischer,
Paterson.

Critical revision of the manuscript for important in-
tellectual content: Bell, Hatch, Fischer, Cernat, Paterson,
Gruenei, Gill, Bronskill, Anderson, Rochon.

Statistical analysis: Bell, Cernat.

Obtained funding: Bell, Gill, Bronskill, Anderson,
Rochon.

Administrative, technical, or material support: Fischer,
Cernat.

Study supervision: Anderson, Rochon.

Financial Disclosures: Dr Hatch has been employed
by the University of Toronto and the Toronto West-
ern Hospital to coordinate clinical trials sponsored by
Alcon and Novartis. Dr Fischer was last employed by
Bayer Inc in 2004. No other authors have any poten-
tial or real conflicts of interest to declare. Dr Cernat
performed the statistical analysis for this study and
declares no conflicts of interest.

Funding/Support: This work was supported by Team
Grant OTG-88591 from the Canadian Institutes of
Health Research (CIHR) Institute of Nutrition, Me-
tabolism, and Diabetes, and by an Interdisciplinary Ca-
Pacity Enhancement Grant, HOA-80075, from the
CIHR Institute of Gender and Health and the CIHR
Institute of Aging. Dr Bell is supported by a New
Investigator Award from the CIHR Institute of Aging.
This study was conducted at the Institute for Clinical
Evaluative Sciences (ICES), which is funded by an
annual grant from the Ontario Ministry of Health and
Long-Term Care (MOHLTC).

Role of the Sponsors: The funding agencies had no
role in the design and conduct of the study; collec-
tion, management, analysis, or interpretation of the
data, or preparation, review, or approval of the manu-
script.

Disclaimer: The opinions, results, and conclusions re-
ported in this article are those of the authors and are
independent from the funding sources. No endorse-
ment by ICES or the Ontario MOHLTC is intended or
should be inferred.

REFERENCES

1. Wei JT, Callhoue E, Jacobsen SJ. Urologic Diseases in

2. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The
development of human benign prostatic hyperplasia with

3. McConnell JD, Roehrborn CG, Bautista OM, et al; Medical
Therapy of Prostatic Symptoms (MTOPS) Re-
search Group. The long-term effect of doxazosin, fi-
nasteride, and combination therapy on the clinical pro-

//www.boehringer-ingelheim.com/corporate

5. Blouin MC, Blouin J, Perreault S, Lapointe A, Dragomir A. Intraoperative floppy-iris syndrome as-

iris behaviour during cataract surgery: asso-
91(4):40-42.

7. Chang DF, Campbell JR. Intraoperative floppy iris
syndrome associated with tamsulosin. J Cataract Re-

multicenter evaluation of cataract surgery in pa-
tients taking tamsulosin (Flomax). Ophthalmology.

9. Cheung CM, Awan MA, Peh KH, Sandramoul S. Incidence of intraoperative floppy iris syndrome in
patients on either systemic or topical alpha1-

10. Cheung CM, Awan MA, Sandramoul S. Preva-
ence and clinical findings of tamsulosin-associated in-
traoperative floppy-iris syndrome. J Cataract Refract

intraoperative floppy iris syndrome in patients on ei-
ther systemic or topical alpha1-adrenoceptor
151.

12. Srinivasan S, Radomski S, Chung J, Plazker T, Singer
C, Slomovic AR. Intraoperative floppy-iris syndrome
during cataract surgery in men using alpha-blockers
for benign prostatic hypertrophy. J Cataract Refract

13. Takmak T, Can I. Clinical features, complica-
tions, and incidence of intraoperative floppy iris
syndrome in patients taking tamsulosin. Eur J Ophthal-

14. Scheven DA, Afshari NA. alpha1(1)-Adrenergic re-
ceptor antagonists and the iris: new mechanistic in-
sights into floppy iris syndrome. Surv Ophthalmol.

15. Pärssinen O, Leppänen E, Keski-Rahkonen P, Mau-
rialia T, Dugue B, Lehtonen M. Influence of tam-
ulosin on the iris and its implications for cataract
190.

Intraoperative clinical practice and risk of early com-
lications after cataract extraction in the United
States, Canada, Denmark, and Spain. Ophthalmology.

17. Desai P, Minassian DC, Reidy A. National cata-
ракt surgery survey 1997-8: a report of the results of
83(12):1336-1340.

18. Nguyen DQ, Sebastian RT, Kyle G. Surgeon’s ex-
eriences of the intraoperative floppy iris syndrome in
the United Kingdom. Eye. 2007;21(3):443-444.

19. Cantrell WA, Bream-Reuwenhorst HR, Steffensmeier
A, Hemerson P, Rogers M, Stamper B. Intraoperative
Floppy iris syndrome associated with alpha1-

20. Armitage JN, Sibanda N, Cathcart PJ, Emberton
M, van der Meulen JH. Mortality in men admitted to
hospital with acute urinary retention: database analysis.
BMJ. 2007;335(7631):1199-1202.


22. Halb MS, Bunce CV, Fraser SG. The role of case
mix in the relation of volume and outcome in
89(9):1134-1146.

23. Gurbaxani A, Packard R. Intracameral phenyl-
ephrine to prevent floppy iris syndrome during cata-
ract surgery in patients on tamsulosin. Eye. 2007;
21(3):331-332.

24. Bendel RE, Phillips MB. Preoperative use of atro-
pine to prevent intraoperative floppy-iris syndrome
in patients taking tamsulosin. J Cataract Refract

25. Vilet N, LI, Jonsson NG; teamEPSWA. The Endo-
phthalmitis Population Study of Western Aus-